Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
Flatiron Health, Inc.; Foundation Medicine, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of mNSCLC or ES-SCLC
Planned initiation of SOC systemic anti-cancer treatment
Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563
You may not be if
\- Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent
Clareo Health | Prospective Clinicogenomic Program
